ArticleNephrology (Carlton, Vic.)2025
IgA Nephropathy With Membranoproliferative Pattern and Resistance to Immunosuppressive Therapy in Two Patients With Cofactor I Pathogenic Variant.
Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement system (CS) overactivation is one of the main causes of kidney damage in IgA nephropathy (IgAN), and it mainly involves the alternative pathway (AP). Additionally, pathogenic complement variants in CS-related genes are reported in IgAN with associated thrombotic microangiopathy (TMA). Here we report two patients with IgAN presenting membranoproliferative pattern, isolated C3 hypocomplementemia, resistance to multiple lines of immunosuppressive therapy, familiarity for proteinuric chronic kidney disease and pathogenic rare variants in cofactor I (CFI). To the best of our knowledge, no other cases of IgAN patients with a similar phenotype and genotype were previously reported in the literature. This work highlights the essential role of deep phenotyping and genotyping in providing tailored treatment strategies in IgAN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.